详细内容
|
1.Dou, Q.P., and Zonder, J.A.Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome systemCurr. Cancer Drug Targets14(6)517-536(2014) 2.Zhou, H.J., Aujay, M.A., Bennett, M.K., et al.Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)J. Med. Chem.52(9)3028-3038(2009) 3.Zhang, W., and Sidhu, S.S.Development of inhibitors in the ubiquitination cascadeFEBS Lett.588(2)356-367(2014) 4.Demo, S.D., Kirk, C.J., Aujay, M.A., et al.Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeCancer Res.67(13)6383-6391(2007)
|